Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension Study of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease

NCT02633293 is registered in ClinicalTrials.gov with United Therapeutics as lead sponsor.

NCT NCT02633293
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02633293 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension Study of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Lead sponsor
United Therapeutics
Phase
Phase 2/3
Overall status
Terminated
Start date
September 15, 2016
Completion date
August 1, 2021
Enrollment
243 (actual)
Sites
92

Conditions

As the registry lists them; a condition with its own page is linked.

combined pulmonary fibrosis and emphysema, interstitial lung disease, pulmonary hypertension